An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

The FDA approved 2025-2026 COVID vaccines from Pfizer (Comirnaty), Moderna (Spikevax, mNexspike), and Novavax (Nuvaxovid), the companies announced on Wednesday. But the agency removed one of the ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...

Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.